PMID- 26014293
OWN - NLM
STAT- MEDLINE
DCOM- 20160429
LR  - 20240104
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 33
IP  - 25
DP  - 2015 Sep 1
TI  - Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced 
      Melanoma.
PG  - 2780-8
LID - 10.1200/JCO.2014.58.3377 [doi]
AB  - PURPOSE: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 
      1-derived oncolytic immunotherapy designed to selectively replicate within tumors 
      and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance 
      systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients 
      with unresected stage IIIB to IV melanoma in a randomized open-label phase III 
      trial. PATIENTS AND METHODS: Patients with injectable melanoma that was not 
      surgically resectable were randomly assigned at a two-to-one ratio to 
      intralesional T-VEC or subcutaneous GM-CSF. The primary end point was durable 
      response rate (DRR; objective response lasting continuously >/= 6 months) per 
      independent assessment. Key secondary end points included overall survival (OS) 
      and overall response rate. RESULTS: Among 436 patients randomly assigned, DRR was 
      significantly higher with T-VEC (16.3%; 95% CI, 12.1% to 20.5%) than GM-CSF 
      (2.1%; 95% CI, 0% to 4.5%]; odds ratio, 8.9; P < .001). Overall response rate was 
      also higher in the T-VEC arm (26.4%; 95% CI, 21.4% to 31.5% v 5.7%; 95% CI, 1.9% 
      to 9.5%). Median OS was 23.3 months (95% CI, 19.5 to 29.6 months) with T-VEC and 
      18.9 months (95% CI, 16.0 to 23.7 months) with GM-CSF (hazard ratio, 0.79; 95% 
      CI, 0.62 to 1.00; P = .051). T-VEC efficacy was most pronounced in patients with 
      stage IIIB, IIIC, or IVM1a disease and in patients with treatment-naive disease. 
      The most common adverse events (AEs) with T-VEC were fatigue, chills, and 
      pyrexia. The only grade 3 or 4 AE occurring in >/= 2% of T-VEC-treated patients was 
      cellulitis (2.1%). No fatal treatment-related AEs occurred. CONCLUSION: T-VEC is 
      the first oncolytic immunotherapy to demonstrate therapeutic benefit against 
      melanoma in a phase III clinical trial. T-VEC was well tolerated and resulted in 
      a higher DRR (P < .001) and longer median OS (P = .051), particularly in 
      untreated patients or those with stage IIIB, IIIC, or IVM1a disease. T-VEC 
      represents a novel potential therapy for patients with metastatic melanoma.
CI  - (c) 2015 by American Society of Clinical Oncology.
FAU - Andtbacka, Robert H I
AU  - Andtbacka RH
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Kaufman, Howard L
AU  - Kaufman HL
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA. 
      howard.kaufman@rutgers.edu.
FAU - Collichio, Frances
AU  - Collichio F
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Amatruda, Thomas
AU  - Amatruda T
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Senzer, Neil
AU  - Senzer N
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Chesney, Jason
AU  - Chesney J
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Delman, Keith A
AU  - Delman KA
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Spitler, Lynn E
AU  - Spitler LE
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Puzanov, Igor
AU  - Puzanov I
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Agarwala, Sanjiv S
AU  - Agarwala SS
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Milhem, Mohammed
AU  - Milhem M
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Cranmer, Lee
AU  - Cranmer L
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Curti, Brendan
AU  - Curti B
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Lewis, Karl
AU  - Lewis K
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Ross, Merrick
AU  - Ross M
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Guthrie, Troy
AU  - Guthrie T
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Linette, Gerald P
AU  - Linette GP
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Daniels, Gregory A
AU  - Daniels GA
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Harrington, Kevin
AU  - Harrington K
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Middleton, Mark R
AU  - Middleton MR
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Miller, Wilson H Jr
AU  - Miller WH Jr
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Zager, Jonathan S
AU  - Zager JS
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Ye, Yining
AU  - Ye Y
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Yao, Bin
AU  - Yao B
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Li, Ai
AU  - Li A
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Doleman, Susan
AU  - Doleman S
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - VanderWalde, Ari
AU  - VanderWalde A
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Gansert, Jennifer
AU  - Gansert J
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
FAU - Coffin, Robert S
AU  - Coffin RS
AD  - Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake 
      City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New 
      Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, 
      Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, 
      Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD 
      Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, 
      Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University 
      School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma 
      Center, San Francisco; Gregory A. Daniels, University of California San Diego 
      Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari 
      Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, 
      Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University 
      Hospital and Health Network, Bethlehem, and Temple University School of Medicine, 
      Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa 
      City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. 
      Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado 
      Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; 
      Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, 
      Washington University School of Medicine, St Louis, MO; Kevin Harrington, 
      Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, 
      National Institute for Health Research Biomedical Research Centre, Oxford, United 
      Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and 
      Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00769704
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150526
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antineoplastic Agents)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
CIN - Nat Rev Clin Oncol. 2015 Aug;12(8):438. PMID: 26077044
CIN - Ann Surg Oncol. 2016 Dec;23(13):4126-4129. PMID: 27380046
CIN - Nature. 2018 May;557(7704):150-151. PMID: 29740143
MH  - Adjuvants, Immunologic/administration & dosage/adverse effects/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Chills/chemically induced
MH  - Fatigue/chemically induced
MH  - Female
MH  - Fever/chemically induced
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/*drug effects/immunology
MH  - *Herpesvirus 1, Human
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Injections, Intralesional
MH  - Male
MH  - Melanoma/*drug therapy/*immunology/mortality/prevention & control/secondary
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Odds Ratio
MH  - *Oncolytic Virotherapy
MH  - *Oncolytic Viruses
MH  - Skin Neoplasms/*drug therapy/*immunology/mortality/pathology/prevention & control
MH  - Survival Analysis
MH  - Time Factors
MH  - Treatment Outcome
MH  - United States/epidemiology
EDAT- 2015/05/28 06:00
MHDA- 2016/04/30 06:00
CRDT- 2015/05/28 06:00
PHST- 2015/05/28 06:00 [entrez]
PHST- 2015/05/28 06:00 [pubmed]
PHST- 2016/04/30 06:00 [medline]
AID - JCO.2014.58.3377 [pii]
AID - 10.1200/JCO.2014.58.3377 [doi]
PST - ppublish
SO  - J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 
      May 26.